Diagnosis and Management of Extrahepatic Portal Vein Obstruction (EHPVO)

Key Diagnostic Features

The American Association for the Study of Liver Diseases suggests that EHPVO typically presents in younger patients with acute variceal bleeding as the initial manifestation, contrasting with the fortuitous findings more common in modern diagnosis 1
The severity of portal hypertension in EHPVO contrasts sharply with normal transaminases, alkaline phosphatase, and gamma-glutamyl transferase, which is characteristic of EHPVO rather than cirrhosis 1
The combination of splenomegaly and suspected hypersplenism is consistent with portal hypertension from venous obstruction 1
The absence of jaundice, ascites, or encephalopathy despite massive bleeding strongly suggests non-cirrhotic portal hypertension 1

Immediate imaging with CT or MRI with portal venous phase contrast is essential to confirm portal vein patency versus thrombosis/cavernomatous transformation, as recommended by the American College of Radiology 1, 2
The hallmark finding of EHPVO is cavernomatous transformation—porto-portal collaterals that develop when the portal vein lumen obliterates after acute thrombosis 1
Investigate for underlying prothrombotic disorders, such as personal or familial history of unprovoked DVT or inherited thrombophilias, in young patients with EHPVO 1
Rule out splenic vein thrombosis, which can cause isolated left-sided portal hypertension with gastric varices and splenomegaly, as suggested by the American College of Radiology 3

A restrictive transfusion strategy targeting hemoglobin 7-9 g/dL is superior to liberal transfusion, reducing mortality and rebleeding risk, according to the Clinical and Molecular Hepatology guidelines 4
Initiate vasoactive drugs, such as terlipressin, octreotide, or somatostatin, immediately before endoscopy to reduce splanchnic blood flow and portal pressure, as recommended by the American College of Radiology 5
Start antibiotic prophylaxis immediately upon admission to reduce mortality, bacterial infections, and rebleeding, as suggested by the American College of Radiology 4, 5

Combination therapy with non-selective beta-blockers (NSBBs) plus repeat endoscopic variceal ligation (EVL) is the standard approach for preventing rebleeding, according to the Clinical and Molecular Hepatology guidelines 4, 7
Titrate NSBBs to resting heart rate 55-60 bpm, reducing portal pressure by >20% or to <12 mmHg, as recommended by the American Association for the Study of Liver Diseases 4, 7
Repeat EVL every 2-8 weeks until variceal eradication, then perform surveillance endoscopy 1-6 months after eradication, and every 6-12 months thereafter, as suggested by the Clinical and Molecular Hepatology guidelines 4

Anticoagulation should be strongly considered in EHPVO patients after acute bleeding is controlled, particularly if prothrombotic conditions are identified, as recommended by the American Association for the Study of Liver Diseases 1
Assess for recanalization status at 6-12 months with CT, and consider anticoagulation to prevent recurrent thrombosis and promote portal vein recanalization, as suggested by the American Association for the Study of Liver Diseases 1
Screen for varices and monitor for biliary complications, such as portal cholangiopathy, and watch for recurrent bleeding, as recommended by the American Association for the Study of Liver Diseases 1